Utilizing multiple ligand simultaneous docking and drug repositioning approaches, we have identified Bazedoxifene [marketed as DUAVEE (Bazedoxifene with conjugated estrogens) by Pfizer in the prevention and treatment of postmenopausal osteoporosis] as novel inhibitor of IL-6 and GP130 protein-protein interactions [36]. Here, IL6 is linked to postmenopausal osteoporosis.